Cargando…
Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer
BACKGROUND: Interleukin-13 Receptor α2 (IL-13Rα2) is a tumor-associated antigen and target for cancer therapy. Since IL-13Rα2 is heterogeneously overexpressed in a variety of human cancers, it would be highly desirable to uniformly upregulate IL-13Rα2 expression in tumors for optimal targeting. METH...
Autores principales: | Fujisawa, Toshio, Joshi, Bharat H, Puri, Raj K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096924/ https://www.ncbi.nlm.nih.gov/pubmed/21477288 http://dx.doi.org/10.1186/1479-5876-9-37 |
Ejemplares similares
-
Histone deacetylase inhibitiors enhance sensitivity of murine sarcoma tumors to IL-13-PE immunotoxin-based cancer therapy by upregulating IL-13Rα2 expression in vitro and in vivo
por: Fujisawa, Toshio, et al.
Publicado: (2013) -
Analysis of interleukin-13 receptor alpha2 expression as a prognostic biomarker in surgically resected pancreatic cancer patients
por: Fujisawa, Toshio, et al.
Publicado: (2015) -
Interleukin 13 receptor alpha 2 directed immunotherapy targets hepatic fibrosis and tumorigenesis induced by choline deficient diet in an in vivo mouse model of nonalcoholic steatohepatitis
por: Fujisawa, Toshio, et al.
Publicado: (2014) -
IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer
por: Fujisawa, Toshio, et al.
Publicado: (2021) -
Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models
por: Nakashima, Hideyuki, et al.
Publicado: (2010)